◂ Announcements

Jan 10, 2020ACQUISITIONBelgium

VolitionRx subsidiary acquires Octamer GmbH for $725,000

VolitionRx Limited's subsidiary Belgian Volition SPRL closed on the acquisition of epigenetic reagent company Octamer GmbH for $725,000 (€650,000) in cash and stock. The deal secures supply of key components for Volition's Nu.Q cancer tests.

Value

$725K

Status

Completed

Productsrecombinant nucleosomesNu.Q tests for colorectal and prostate cancers

CompaniesVolitionRx Limited acquirer Belgian Volition SPRL acquirer Octamer GmbH target

Sectors#Medical Devices

“This acquisition means that we will be working with one of the world's leading nucleosome experts, Dr Adrian Schomburg.”proactiveinvestors.com

1 source
proactiveinvestors.comVolitionRx subsidiary closes on $725K acquisition of Octamer GmbH | NYSE-A:VNRXPatrick M. GrahamJan 10, 2020

Summarized from public sources; check the original articles before acting on it.

Similar announcements

Nov 6, 2026ACQUISITIONUnited States$9.90B
Danaher to acquire Masimo for $9.9 billion
Danaher acquirer Masimo target mdtvnow.com
Nov 5, 2026ACQUISITIONUnited States
Curewell Capital to acquire majority stake in ECA Medical
Curewell Capital acquirer ECA Medical target businesswire.com
Nov 5, 2026ACQUISITIONUnited States$538.0M
ZOLL Medical to acquire Itamar Medical for $538M
Asahi Kasei investor ZOLL Medical Corporation acquirer forpressrelease.com
Nov 4, 2026ACQUISITIONPlano, Texas, United States$2.25M
OSTEONIC acquires controlling stake in FoxEyes for 3 billion won
OSTEONIC FoxEyes target en.edaily.co.kr
Nov 3, 2026ACQUISITIONDeerfield, Illinois, United States
Vantive to divest majority of hemodialysis assets to Rockwell Medical
Vantive Rockwell Medical acquirer prnewswire.com
Nov 3, 2026ACQUISITIONMedolla, Italy, Italy$125.0M
Rockwell Medical to acquire Vantive's hemodialysis business for $400-450M annual revenue
Rockwell Medical acquirer Vantive target sec.gov nasdaq.com securities.io

Loading…